Multimedia News

ASCO 2010 Presentation
Highlights and video from the poster presentation made at ASCO 2010

Provectus Updates Shareholders on 2009 Year-to-date Accomplishments
Progress Made In Therapies for Metastatic Melanoma, Atopic Dermatitis and Psoriasis

ASCO 2009 Presentation
Highlights and video from the poster presentation made at ASCO 2009

6th International Symposium on Melanoma and Other Cutaneous Malignancies
Professor John F. Thompson,M.D. presentated interim results of the phase 2 clinical trial of PV-10 for melanoma in March 2009.

Perspectives In Melanoma Conference XII Presentation
Professor John F. Thompson,M.D. presented interim results of Phase 2 PV-10 for melanoma trial in October 2008.

PV-10 for Melanoma Story Airs in Australia
Video interviews with Professor John Thompson and a patient who was involved in the Phase 2 study of PV-10 for melanoma.

SCC 2008 Presentation
Professor John Thompson of the Sydney Melanoma Unit presents preliminary findings from Phase 2 study of PV-10 for melanoma.

Provectus Preview
30 second preview of Provectus' multimedia annual report.

Clinical Trials Updates

Clinical trial information at ClinicalTrials.gov

Summary of the clinical effects of PV-10 on melanoma

Melanoma Research Publishes PV-10 Article

[video] PV-10 for melanoma story airs on Australian TV

Information on the Compassionate Use Program for PV-10

Subscribe to the Provectus News newsletter

Opening a New Front in the
War Against Cancer

Provectus Pharmaceuticals is developing advanced therapies designed to:

Target and destroy the deadliest cancers – melanoma, liver & breast – while eliminating side effects.
- Phase 1 clinical trials for liver cancer, metastatic melanoma, and recurrent breast cancer have been successfully completed.
- A Phase 2 clinical trial for metastatic melanoma has been successfully completed. A poster entitled "Chemoablation of Metastatic Melanoma with Rose Bengal (PV-10)", presented at the ASCO 2010 annual meeting, summarizes interim Phase 2 clinical data on changes in visceral and nodal metastases following chemoablation of cutaneous melanoma lesions with PV-10.
- Preparations are underway for a Phase 3 randomized controlled study of PV-10 for metastatic melanoma suitable for Special Protocol Assessment. Paths for accelerated approval for PV-10 to treat metastatic melanoma in the USA and abroad are being evaluated.
- A Compassionate Use Program for PV-10 is being conducted as an expanded access study.
- A Rose Bengal presentation from September 2006 and a peer-reviewed publication from December 2008 include summaries of the clinical effects of PV-10 on melanoma.
- For further clinical trial information, see the Melanoma Clinical Trial Update page.
Treat severe psoriasis and atopic dermatitis.
- Phase 2 clinical trials for psoriasis and atopic dermatitis have been successfully completed.
- A Phase 2c randomized clinical trial for psoriasis is underway.

Provectus has developed groundbreaking biotechnologies to augment vaccine production and detect viruses (including an innovative “virus hunter” method); preparing to spinout the subsidiary that contains our novel over-the-counter skin care products; and seeks to license patented technologies for therapeutic and cosmetic medical devices.

For further information, read our detailed Research Reports.

In The Media

May 3, 2012

Intralesional Therapies Discussed At the HemOnc Today Melanoma and Cutaneous Malignancies Meeting

The HemOnc Today Melanoma and Cutaneous Malignancies meeting, held April 13-14 2012, included a presentation session entitled "Local Regional Therapy for Melanoma in the Current Therapeutic Era". Two of the session's three presentations discuss the use of intralesional drugs, including PV-10, for treating metastatic melanoma.

May 1, 2012

PV-10, aka Rose Bengal: Intralesional Therapy For Metastatic Melanoma

An article entitled "PV-10, aka Rose Bengal: Intralesional Therapy For Metastatic Melanoma" was published in The Melanoma Letter, Spring 2012 Vol. 30, No. 1. The article, authored by Sanjiv S. Agarwala, MD, discusses the resurgence of intralesional therapies for melanoma and the especially intriguing "bystander" effect seen in Phase 2 studies of PV-10.

April 17, 2012

Rose Bengal: More Than Just a Red Food Dye?

An interview with Craig Dees, Ph.D., CEO of Provectus Pharmaceuticals, appearing in the March 2012 edition of The North Carolina Osteopathic Medical Association News, discusses the treatment of cancer with PV-10, highlighting the direction and advances being made by drug researchers in the fight against cancer.

April 5, 2012

BioCentury Reports on Provectus Phase IIc Psoriasis Results

An article appearing March 26, 2012 in BioCentury reports on the very psitive clinical results from Provectus's Phase IIc trial of PH-10 for psoriasis.

April 2, 2012

Intralesional PV-10 Treatment Shows Promise For Some Melanoma Patients

An article appearing in Medical News Today reports that the results of a non-clinical study performed by the Moffitt Cancer Center and University of South Florida confirm that PV-10 chemoablation of melanoma lesions results in a systemic response and initiates systemic anti-tumor immunity.

March 5, 2012

FDA Grants Approval to Move Forward with Phase III Trial of Metastatic Melanoma Drug PV-10

An article appearing in The Dermatologist covers recent news that the FDA has provided Provectus with guidance about submitting its metastatic melanoma Phase III protocol for review with Special Protocol Assessment (SPA).

Press Releases

May 14, 2012

Provectus Pharmaceuticals Forms Independent Board to Meet Corporate Governance Requirements

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com) announces the Company has formed an independent board to meet corporate governance requirements like that of NASDAQ, which requires a majority of independent Board Members. To accomplish this, Jan E. Koe has been appointed to its Board of Directors and Eric Wachter, Ph.D., has resigned from the Board and named Chief Technology Officer, a new position.

May 9, 2012

Provectus Pharmaceuticals' PV-10 Phase 2 Final Data To Be Presented At 2nd European PostASCO Melanoma Meeting 2012 on June 22, 2012

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com) announces that Phase 2 final data on PV-10 for metastatic melanoma will be presented at the 2nd European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.

May 7, 2012

Provectus Pharmaceuticals, Inc.'s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com) today announced that its May 3rd RetailInvestorConferences.com presentation is now available for on-demand viewing.

April 30, 2012

Provectus Pharmaceuticals, Inc. to Webcast Live at RetailInvestorConferences.com on May 3rd

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com) today announced that Craig Dees, Ph.D., CEO, will be presenting at RetailInvestorConferences.com.

April 24, 2012

Provectus Updates Shareholders in Its Annual CEO Letter

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com) updates its shareholders on the clinical progress and corporate developments the company achieved during 2011. The company also provides insight on its accomplishments and plans for the first part of 2012.

April 10, 2012

Phase 2 Data on Provectus's PV-10 to Be Presented at the HemOnc Today - Melanoma and Cutaneous Malignancies Conference on April 13, 2012

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com) announces that data from its Phase 2 study of PV-10 for metastatic melanoma will be presented at the HemOnc Today - Melanoma and Cutaneous Malignancies Conference on April 13, 2012.